Benchmark Downgrades Humacyte to Speculative Buy, Lowers Price Target to $1

Benzinga Newsdesk www.benzinga.com Negative 89.4%

Neg 89.4% Neu 0% Pos 0%

Benchmark analyst Bruce D. Jackson downgrades Humacyte (NASDAQ:HUMA) from Buy to Speculative Buy and lowers the price target from $10 to $1.